Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (APPROPRIATE Study)

NCT03539419 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03539419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (APPROPRIATE Study)
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
June 12, 2018
Completion date
October 31, 2020
Enrollment
153 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis